AllianceBernstein
SVNT

AllianceBernstein’s SAVIENT PHARMACEUTICALS INC SVNT Stock Holding History

AllianceBernstein’s Portfolio SVNT Stock Details SVNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-500
Closed – – 3556
2013
Q2 		$0 Buy
+500
New +$348 ﹤0.01% 3279

Other funds holding SVNT

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AllianceBernstein's SVNT Position: Q3 2013 in Review

AllianceBernstein sold out of SAVIENT PHARMACEUTICALS INC (SVNT) in Q3 2013, closing a stake of 500 shares.

AllianceBernstein first reported a position in SVNT in Q2 2013 and held it in 1 quarter. The position peaked at $0 in Q2 2013. 41 funds tracked by Wall St. Rank hold SVNT as of Q3 2013.

  • AllianceBernstein reported no remaining SAVIENT PHARMACEUTICALS INC position as of Q3 2013 after selling out during the quarter.
  • AllianceBernstein sold 500 SAVIENT PHARMACEUTICALS INC shares in Q3 2013.
  • AllianceBernstein first reported a position in SAVIENT PHARMACEUTICALS INC in Q2 2013 and held it in 1 quarter.
  • AllianceBernstein's SAVIENT PHARMACEUTICALS INC position peaked at $0 in Q2 2013.
  • 41 funds tracked by Wall St. Rank held SAVIENT PHARMACEUTICALS INC as of Q3 2013.

Based on AllianceBernstein's 13F filing for Q3 2013, filed 14 Nov 2013.